Meng Huijuan, Zhang Yulan, Chen Youguo
The Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu, China.
The Department of Obstetrics and Gynecology, Suzhou Hospital of Traditional Chinese Medicine, Suzhou 215003, Jiangsu, China.
Evid Based Complement Alternat Med. 2021 Dec 31;2021:4355805. doi: 10.1155/2021/4355805. eCollection 2021.
To explore the diagnosis value of colposcope combined with serum squamous cell carcinoma antigen (SCC-Ag), carbohydrate antigen 125 (CA125), and carcinoembryonic antigen (CEA) for moderate to advanced cervical cancer patients treated with modified Fuzheng Peiyuan decoction.
The clinical data of 43 moderate to advanced cervical cancer patients treated in Suzhou Hospital of Traditional Chinese Medicine from July 2018 to July 2019 were selected for the retrospective analysis, and 43 healthy women undergoing physical examination in our medical center in the same period were selected as the control group. The cervical cancer patients accepted the modified Fuzheng Peiyuan decoction treatment, the detection of SCC-Ag, CA125, and CEA and colposcope examination were performed to all research subjects, and the changes in indicators such as KPS scores and lesion perfusion parameters in cervical cancer patients before and after treatment were monitored, so as to analysis the clinical diagnosis value of combined diagnosis in treated patients.
After treatment, the mean KPS scores were greatly higher and various blood perfusion parameters of lesions and serum SCC-Ag, CA125, and CEA levels were remarkably lower than before ( value <0.001 for all); the area under the curve of combined test was significantly larger than that of single test, and the sensitivity and specificity of the combined test were the highest; and after medication, the total incidence rate of toxic and side effects was 11.63%.
Fuzheng Peiyuan decoction has significant effect in treating moderate to advanced cervical cancer, and colposcope combined with serum test presents more accurate and credible diagnosis results and has great significance for future treatment, which shall be promoted and applied.
探讨阴道镜联合血清鳞状细胞癌抗原(SCC-Ag)、糖类抗原125(CA125)及癌胚抗原(CEA)对采用改良扶正培元汤治疗的中晚期宫颈癌患者的诊断价值。
选取2018年7月至2019年7月在苏州市中医医院接受治疗的43例中晚期宫颈癌患者的临床资料进行回顾性分析,选取同期在本医疗中心进行体检的43例健康女性作为对照组。对宫颈癌患者采用改良扶正培元汤治疗,对所有研究对象进行SCC-Ag、CA125及CEA检测和阴道镜检查,并监测宫颈癌患者治疗前后KPS评分及病灶灌注参数等指标的变化,以分析联合诊断对治疗患者的临床诊断价值。
治疗后,患者的平均KPS评分显著升高,病灶的各项血流灌注参数及血清SCC-Ag、CA125、CEA水平均显著低于治疗前(均P<0.001);联合检测的曲线下面积显著大于单项检测,联合检测的敏感度和特异度最高;用药后,毒副作用总发生率为11.63%。
扶正培元汤治疗中晚期宫颈癌疗效显著,阴道镜联合血清学检测诊断结果更准确可靠,对后续治疗具有重要意义,值得推广应用。